Status:
TERMINATED
Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborating Sponsors:
GE Healthcare
Conditions:
Breast Cancer
Eligibility:
FEMALE
30+ years
Phase:
NA
Brief Summary
This research study is comparing Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) to MRI as a screening tool for breast cancer.
Detailed Description
This research study is being done to test how well a contrast enhanced mammogram compares to MRI in screening for breast cancer in people who are at higher risk for developing breast cancer. Standard...
Eligibility Criteria
Inclusion
- Women
- Age \> or equal to 30 years
- High risk (\>20% lifetime risk)
- Has a bilateral mammogram within the last 7 months
- Has had a same day high risk screening MRI
Exclusion
- Participants who have a known allergy or contraindication to iodinated contrast.
- Participants who have a known allergy to food or medications.
- Participants who have renal insufficiency or failure.
- Participants who are pregnant or breastfeeding.
- Participants with a concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT02275871
Start Date
November 1 2014
End Date
January 1 2020
Last Update
March 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215